Key Performance
More- Earnings Score: N/A
- Momentum Score: 49
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics plc has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product by the Galien Foundation, recognizing excellence in its next-generation T cell therapy development. The award was presented by a committee of 12 UK healthcare experts and reflects the company's commitment to translating scientific research into cancer and autoimmune disease treatments.
06/12/2026, 4:00 AM • GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics plc announced it will present at William Blair's 46th Annual Growth Stock Conference on June 2, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026, with CEO Dr. Christian Itin as presenter. The company also announced the online publication of an abstract for the American Society of Clinical Oncology Annual Meeting 2026 and reported its Q1 2026 financial results.
05/27/2026, 7:00 AM • GlobeNewswire
Autolus Therapeutics reported $74.3 million in full-year 2025 AUCATZYL net product revenue and $23.3 million in Q4 2025 revenue. The company launched AUCATZYL in the UK following NICE approval and expects 2026 revenue of $120-135 million with a shift to positive gross margin. Real-world data from the ROCCA consortium confirmed high clinical activity with favorable safety profiles. The company is advancing obe-cel in multiple indications including pediatric ALL, lupus nephritis, and progressive MS, with clinical data expected throughout 2026-2028.
03/27/2026, 7:00 AM • GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics plc announced participation in two upcoming investor conferences in March 2026 (TD Cowen Health Care Conference on March 3 and Jefferies Biotech on the Beach Summit on March 10). The company also announced preliminary unaudited fourth quarter and full year 2025 net product revenue from AUCATZYL® sales, along with pipeline advancements and 2026 outlook.
02/24/2026, 7:00 AM • GlobeNewswire
The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL®, a CAR T cell therapy developed by Autolus Therapeutics, as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in England and Wales.
11/25/2025, 4:00 AM • GlobeNewswire
Autolus Therapeutics presented promising Phase 1 clinical trial data for obe-cel, a CAR T cell therapy targeting severe refractory systemic lupus erythematosus, showing high remission rates and potential for meaningful clinical impact.
10/27/2025, 7:00 AM • GlobeNewswire
Autolus Therapeutics initiated a Phase 1 clinical trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis, dosing the first patient at University College London Hospitals NHS Foundation Trust to evaluate the therapy's safety and potential efficacy.
10/20/2025, 7:00 AM • GlobeNewswire
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics reported Q2 2025 net product sales of $20.9 million for AUCATZYL®, received marketing authorization in the UK and EU, and presented long-term data from the FELIX trial demonstrating potential for long-term remission in relapsed/refractory B-ALL.
08/12/2025, 7:00 AM • GlobeNewswire
Autolus Therapeutics received European marketing authorization for AUCATZYL®, a CAR T cell therapy treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, based on successful FELIX clinical trial results.
07/21/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.